TELA

TELA Bio, Inc. NASDAQ

Healthcare ·Medical - Devices ·US · telabio.com

$0.99

Mkt Cap $46.4M

52w Low $0.50 28.7% of range 52w High $2.20

50d MA $0.73 200d MA $1.21

P/E (TTM) -1.2x

EV/EBITDA -1.8x

P/B 7.3x

Debt/Equity 8.8x

ROE -615.1%

P/FCF -1.9x

RSI (14) —

ATR (14) —

Beta 0.99

50d MA $0.73

200d MA $1.21

Avg Volume 223.6K

About

TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. It provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix pr…

Recent Earnings

Date	Time	Est	Rptd	Surp	Base	Gap%	D1%	D2%	D3%	D4%	D5%	1M%	Guide ▲★
Mar 25, 2026	AMC	-0.18	-0.16	+11.1%	0.69	-2.9%	+8.1%	-2.9%	-18.1%	-10.2%	-17.6%	-2.9%	—
Nov 13, 2025	AMC	-0.17	-0.19	-11.8%	1.11	-5.4%	-10.0%	+2.7%	+6.3%	-2.7%	-4.5%	+1.8%	—
Aug 11, 2025	AMC	-0.18	-0.22	-22.2%	1.86	-4.8%	-14.0%	-21.0%	-14.0%	-15.1%	-8.6%	-15.6%	—
May 8, 2025	AMC	-0.21	-0.25	-19.0%	0.99	+1.0%	+9.0%	+2.0%	-1.1%	-0.1%	-1.1%	+87.8%	—
Mar 20, 2025	AMC	-0.24	-0.23	+4.2%	2.34	-18.8%	-37.2%	-40.2%	-47.0%	-44.9%	-41.5%	-62.0%	—
Nov 7, 2024	AMC	-0.37	-0.42	-13.5%	2.99	-2.7%	+3.0%	-1.7%	+4.0%	+2.3%	+1.7%	+1.3%	—
Aug 12, 2024	AMC	-0.45	-0.51	-13.3%	4.01	-20.2%	-22.9%	-24.4%	-23.4%	-22.4%	-23.4%	-34.2%	—
May 9, 2024	AMC	-0.48	-0.23	+52.1%	4.94	+9.9%	+16.8%	+17.4%	+17.8%	+21.1%	+28.7%	+12.6%	—
Mar 21, 2024	AMC	-0.44	-0.53	-20.5%	5.35	+4.5%	+7.1%	+1.7%	+3.9%	+4.9%	+6.0%	-14.6%	—
Nov 9, 2023	AMC	-0.52	-0.45	+13.5%	5.73	-12.7%	-19.4%	-21.5%	-20.8%	-16.2%	-17.1%	-7.7%	—
Aug 9, 2023	AMC	-0.58	-0.46	+20.7%	9.07	-2.9%	-3.3%	-1.0%	+0.3%	-0.3%	-0.8%	-1.3%	—
May 11, 2023	AMC	-0.51	-0.63	-23.5%	9.96	-1.8%	-3.7%	-4.8%	-4.9%	-3.0%	-3.7%	+10.7%	—

Recent Analyst Ratings

Date	Firm	Action	Grade	Target	Base	Open	Gap%	D1%	D2%	D3%	D4%	D5%
Mar 27	Citizens	Maintains	Market Outperform → Market Outperform	—	$0.75	$0.73	-2.7%	-10.2%	-24.3%	-16.9%	-23.8%	-19.9%
Mar 25	Piper Sandler	Maintains	Neutral → Neutral	—	$0.76	$0.76	-0.0%	-9.4%	-2.0%	-12.0%	-25.8%	-18.6%
Mar 25	Lake Street	Maintains	Buy → Buy	—	$0.76	$0.76	-0.0%	-9.4%	-2.0%	-12.0%	-25.8%	-18.6%
Mar 25	Canaccord Genuity	Maintains	Buy → Buy	—	$0.76	$0.76	-0.0%	-9.4%	-2.0%	-12.0%	-25.8%	-18.6%
Dec 1	Lake Street	Maintains	Buy → Buy	—	$1.15	$1.16	+0.9%	-1.7%	-0.9%	+0.0%	-0.9%	+0.0%
Nov 18	Canaccord Genuity	Maintains	Buy → Buy	—	$1.14	$1.23	+7.9%	+3.5%	-5.3%	-7.0%	+2.6%	+0.0%
Nov 14	Piper Sandler	Maintains	Neutral → Neutral	—	$1.11	$1.05	-5.4%	-10.0%	+2.7%	+6.3%	-2.7%	-4.5%
Nov 14	Citizens	Maintains	Market Outperform → Market Outperform	—	$1.11	$1.05	-5.4%	-10.0%	+2.7%	+6.3%	-2.7%	-4.5%
Mar 21	Piper Sandler	Downgrade	Overweight → Neutral	—	$2.34	$1.90	-18.8%	-37.2%	-40.2%	-47.0%	-44.9%	-41.5%
Mar 21	Canaccord Genuity	Maintains	Buy → Buy	—	$2.34	$1.90	-18.8%	-37.2%	-40.2%	-47.0%	-44.9%	-41.5%
Mar 21	Citizens Capital Markets	Maintains	Market Outperform → Market Outperform	—	$2.34	$1.90	-18.8%	-37.2%	-40.2%	-47.0%	-44.9%	-41.5%
Nov 8	Piper Sandler	Maintains	Overweight → Overweight	—	$2.99	$2.91	-2.7%	+3.0%	-1.7%	+4.0%	+2.3%	+1.7%
Oct 4	Canaccord Genuity	Maintains	Buy → Buy	—	$2.52	$2.53	+0.4%	+7.1%	+4.0%	-0.8%	-3.6%	-5.6%
Aug 13	JMP Securities	Maintains	Market Outperform → Market Outperform	—	$4.01	$3.20	-20.2%	-22.9%	-24.4%	-23.4%	-22.4%	-23.4%
Aug 13	Piper Sandler	Maintains	Overweight → Overweight	—	$4.01	$3.20	-20.2%	-22.9%	-24.4%	-23.4%	-22.4%	-23.4%
Aug 13	Lake Street	Maintains	Buy → Buy	—	$4.01	$3.20	-20.2%	-22.9%	-24.4%	-23.4%	-22.4%	-23.4%
Aug 13	Canaccord Genuity	Maintains	Buy → Buy	—	$4.01	$3.20	-20.2%	-22.9%	-24.4%	-23.4%	-22.4%	-23.4%
Jul 25	Canaccord Genuity	Maintains	Buy → Buy	—	$4.58	$4.60	+0.4%	-1.7%	+0.4%	-0.7%	-3.3%	-2.8%
May 10	Piper Sandler	Maintains	Overweight → Overweight	—	$4.94	$5.43	+9.9%	+16.8%	+17.4%	+17.8%	+21.1%	+28.7%
Mar 22	JMP Securities	Maintains	Market Outperform → Market Outperform	—	$5.35	$5.59	+4.5%	+7.1%	+1.7%	+3.9%	+4.9%	+6.0%
Mar 22	Piper Sandler	Maintains	Overweight → Overweight	—	$5.35	$5.59	+4.5%	+7.1%	+1.7%	+3.9%	+4.9%	+6.0%
Dec 27	Lake Street	Maintains	Buy → Buy	—	$6.52	$6.57	+0.8%	-3.5%	-3.2%	+1.5%	+1.5%	+1.4%
Nov 10	JMP Securities	Maintains	Market Outperform → Market Outperform	—	$5.73	$5.00	-12.7%	-19.4%	-21.5%	-20.8%	-16.2%	-17.1%
Mar 28	Canaccord Genuity	Maintains	Buy → Buy	—	$10.49	$10.35	-1.3%	+3.3%	+5.1%	+7.1%	+1.4%	+4.8%
Mar 22	JMP Securities	Maintains	Market Outperform → Outperform	—	$10.49	$10.50	+0.1%	-5.9%	-4.6%	-4.2%	+0.0%	+3.3%
Nov 10	JMP Securities	Maintains	Market Outperform → Market Outperform	—	$6.50	$7.01	+7.8%	+24.6%	+24.8%	+21.8%	+24.6%	+23.1%
Nov 10	Piper Sandler	Maintains	Overweight → Overweight	—	$6.50	$7.01	+7.8%	+24.6%	+24.8%	+21.8%	+24.6%	+23.1%
Aug 13	Piper Sandler	Maintains	Overweight → Overweight	—	$13.13	$13.79	+5.0%	+5.9%	+0.2%	+4.6%	+3.6%	+2.9%
Jul 9	Jefferies	Maintains	Buy → Buy	—	$13.21	$13.90	+5.2%	-1.2%	+2.3%	+0.1%	+4.5%	+7.4%
Jun 18	JMP Securities	Maintains	Market Outperform → Market Outperform	—	$19.91	$20.00	+0.5%	+8.8%	+13.6%	+5.0%	+6.9%	-0.1%
Jun 10	Canaccord Genuity	Maintains	Buy → Buy	—	$16.82	$17.49	+4.0%	-1.8%	+1.1%	+0.3%	+8.7%	+14.0%
May 13	JMP Securities	Maintains	Market Outperform → Market Outperform	—	$11.01	$11.86	+7.7%	+8.7%	+6.5%	+7.4%	+15.8%	+29.4%
Dec 3	JMP Securities	Maintains	Market Outperform → Outperform	—	$12.31	$12.65	+2.8%	+5.3%	+6.7%	-1.9%	+0.5%	-1.3%
Dec 3	Jefferies	Maintains	Buy → Buy	—	$12.31	$12.65	+2.8%	+5.3%	+6.7%	-1.9%	+0.5%	-1.3%
Dec 3	Canaccord Genuity	Maintains	Buy → Buy	—	$12.31	$12.65	+2.8%	+5.3%	+6.7%	-1.9%	+0.5%	-1.3%
Dec 3	PiperJaffray	Maintains	Overweight → Overweight	—	$12.31	$12.65	+2.8%	+5.3%	+6.7%	-1.9%	+0.5%	-1.3%

Recent Filings

8-K · 5.02 !!! Very High

TELA Bio, Inc. -- 8-K 5.02: Executive Change

TELA Bio appointed Doug Evan and Joseph Capper as independent directors, strengthening board governance and potentially signaling confidence in the company's strategic direction.

Apr 30

8-K · 7.01 ! Medium

Unknown — 8-K 7.01: Regulation FD Disclosure

This 8-K filing contains minimal substantive disclosure—just procedural exhibit references—suggesting Tela either made routine announcements or the company chose minimal required disclosure, warranting scrutiny of actual exhibits for material news.

Mar 24

8-K

Unknown — 8-K Filing

TELA's stock price has fallen below Nasdaq's $1 minimum bid requirement, threatening its listing unless the company successfully appeals or reverses the decline within 180 days.

Mar 20

Data updated apr 27, 2026 4:24am · Source: massive.com